Regencell Bioscience (RGC) Competitors

$28.58 +1.67 (+6.21%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$28.03 -0.55 (-1.92%)

As of 05/15/2026 07:58 PM Eastern

RGC vs. ARGX, TEVA, ONC, RVMD, and INSM

Should you buy Regencell Bioscience stock or one of its competitors? MarketBeat compares Regencell Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Regencell Bioscience include argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Revolution Medicines (RVMD), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Regencell Bioscience compare to argenex?

Regencell Bioscience (NASDAQ:RGC) and argenex (NASDAQ:ARGX) are both large-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

In the previous week, Regencell Bioscience had 6 more articles in the media than argenex. MarketBeat recorded 20 mentions for Regencell Bioscience and 14 mentions for argenex. argenex's average media sentiment score of 0.89 beat Regencell Bioscience's score of 0.08 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

argenex has a consensus target price of $1,017.78, suggesting a potential upside of 27.33%. Given argenex's stronger consensus rating and higher possible upside, analysts clearly believe argenex is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

argenex has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
argenex	$4.66B	10.66	$1.29B	$22.46	35.59

argenex has a net margin of 31.31% compared to Regencell Bioscience's net margin of 0.00%. argenex's return on equity of 33.28% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
argenex	31.31%	33.28%	28.16%

Summary

argenex beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Regencell Bioscience (NASDAQ:RGC) are both large-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Regencell Bioscience had 10 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 20 mentions for Regencell Bioscience and 10 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.92 beat Regencell Bioscience's score of 0.08 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, suggesting a potential upside of 21.85%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.35B	2.27	$1.41B	$1.33	25.78
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Regencell Bioscience's net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Regencell Bioscience	N/A	N/A	N/A

Summary

Teva Pharmaceutical Industries beats Regencell Bioscience on 10 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Regencell Bioscience (NASDAQ:RGC) are both large-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Regencell Bioscience had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 20 mentions for Regencell Bioscience and 10 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.67 beat Regencell Bioscience's score of 0.08 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BeOne Medicines presently has a consensus target price of $389.15, suggesting a potential upside of 32.69%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BeOne Medicines has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.02	$286.93M	$4.47	65.61
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

BeOne Medicines has a net margin of 8.94% compared to Regencell Bioscience's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Regencell Bioscience	N/A	N/A	N/A

Summary

BeOne Medicines beats Regencell Bioscience on 12 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Revolution Medicines?

Regencell Bioscience (NASDAQ:RGC) and Revolution Medicines (NASDAQ:RVMD) are both large-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Regencell Bioscience had 11 more articles in the media than Revolution Medicines. MarketBeat recorded 20 mentions for Regencell Bioscience and 9 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 0.67 beat Regencell Bioscience's score of 0.08 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Revolution Medicines has a consensus price target of $103.88, indicating a potential downside of 28.69%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

Regencell Bioscience's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Revolution Medicines	N/A	-83.22%	-59.06%

Summary

Revolution Medicines beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

How does Regencell Bioscience compare to Insmed?

Regencell Bioscience (NASDAQ:RGC) and Insmed (NASDAQ:INSM) are both large-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Regencell Bioscience and Regencell Bioscience both had 20 articles in the media. Insmed's average media sentiment score of 0.68 beat Regencell Bioscience's score of 0.08 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Insmed has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

0.1% of Regencell Bioscience shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Insmed has a consensus price target of $210.95, indicating a potential upside of 93.29%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Regencell Bioscience has higher earnings, but lower revenue than Insmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Insmed	$606.42M	39.01	-$1.28B	-$5.75	N/A

Regencell Bioscience has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Regencell Bioscience's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Insmed	-144.44%	-130.11%	-51.57%

Summary

Insmed beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGC vs. The Competition

Export

Metric	Regencell Bioscience	Medicinal Chemicals Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$14.13B	$7.07B	$4.71B	$12.30B
Dividend Yield	N/A	N/A	5.95%	5.26%
P/E Ratio	N/A	1.07	22.92	25.27
Price / Sales	N/A	0.28	179.15	62.35
Price / Cash	N/A	1.21	50.53	54.86
Price / Book	2,858.00	1,429.48	38.25	6.90
Net Income	-$3.58M	-$1.41M	$113.55M	$334.66M
7 Day Performance	-2.39%	-2.39%	2.44%	0.12%
1 Month Performance	-0.31%	-0.31%	3.25%	-0.18%
1 Year Performance	N/A	N/A	16.68%	30.62%

Regencell Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGC Regencell Bioscience	0.3557 of 5 stars	$28.58 +6.2%	N/A	N/A	$14.13B	N/A	N/A	10	Earnings Report
ARGX argenex	4.7179 of 5 stars	$802.70 -1.2%	$1,017.78 +26.8%	+41.3%	$50.55B	$4.25B	36.19	1,863	Analyst Revision
TEVA Teva Pharmaceutical Industries	4.5332 of 5 stars	$36.26 +1.3%	$41.78 +15.2%	+102.3%	$41.17B	$17.26B	12.70	33,950
ONC BeOne Medicines	4.1294 of 5 stars	$316.55 +0.5%	$391.00 +23.5%	+28.4%	$34.57B	$5.34B	70.49	12,000	News Coverage Analyst Forecast Insider Trade
RVMD Revolution Medicines	2.2906 of 5 stars	$149.94 +2.9%	$103.88 -30.7%	+268.4%	$30.98B	$11.58M	N/A	250

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regencell Bioscience (RGC) Competitors

RGC vs. ARGX, TEVA, ONC, RVMD, and INSM

How does Regencell Bioscience compare to argenex?

Summary

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Summary

How does Regencell Bioscience compare to BeOne Medicines?

Summary

How does Regencell Bioscience compare to Revolution Medicines?

Summary

How does Regencell Bioscience compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regencell Bioscience (RGC) Competitors

RGC vs. ARGX, TEVA, ONC, RVMD, and INSM

How does Regencell Bioscience compare to argenex?

Does the media prefer RGC or ARGX?

Which has more volatility & risk, RGC or ARGX?

Do analysts rate RGC or ARGX?

Do insiders & institutionals have more ownership in RGC or ARGX?

Which has better earnings and valuation, RGC or ARGX?

Is RGC or ARGX more profitable?

Summary

How does Regencell Bioscience compare to Teva Pharmaceutical Industries?

Does the media favor TEVA or RGC?

Which has more risk and volatility, TEVA or RGC?

Do analysts recommend TEVA or RGC?

Do institutionals & insiders have more ownership in TEVA or RGC?

Which has stronger valuation and earnings, TEVA or RGC?

Is TEVA or RGC more profitable?

Summary

How does Regencell Bioscience compare to BeOne Medicines?

Does the media favor ONC or RGC?

Which has more risk and volatility, ONC or RGC?

Do institutionals & insiders have more ownership in ONC or RGC?

Do analysts recommend ONC or RGC?

Which has stronger valuation and earnings, ONC or RGC?

Is ONC or RGC more profitable?

Summary

How does Regencell Bioscience compare to Revolution Medicines?

Does the media refer more to RGC or RVMD?

Which has more volatility & risk, RGC or RVMD?

Do institutionals & insiders believe in RGC or RVMD?

Do analysts prefer RGC or RVMD?

Which has preferable earnings & valuation, RGC or RVMD?

Is RGC or RVMD more profitable?

Summary

How does Regencell Bioscience compare to Insmed?

Does the media refer more to RGC or INSM?

Which has more volatility & risk, RGC or INSM?

Do institutionals & insiders believe in RGC or INSM?

Do analysts prefer RGC or INSM?

Which has preferable earnings & valuation, RGC or INSM?

Is RGC or INSM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC vs. The Competition

Regencell Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools